REG - ValiRx PLC - Broker Option Results

ValiRxAnnouncement

05/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220705:nRSE2847Ra&default-theme=true

RNS Number : 2847R  ValiRx PLC  05 July 2022

ValiRx Plc

("ValiRx" or the "Company")

Broker Option Results

Further to the announcement made on 30 June 2022 by the Company in connection
with the placing to raise £1.5 million (before expenses) (the "Fundraising
Announcement"), ValiRx, a life science company focusing on early-stage cancer
therapeutics and women's health, is pleased to announce that the Broker Option
granted to Turner Pope Investments (TPI) Limited has been fully subscribed,
receiving applications for 10,000,000 Ordinary Shares (representing £1.0
million raised before expenses) available on the same terms as the
Fundraising.

Subject to Admission, trading in the new Ordinary Shares is expected to
commence on Thursday, 7 July 2022.

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meanings as set out in the Company's announcement of 30 June
2022.

The Directors of the Company take responsibility for this announcement.

 

*** ENDS ***

 

 For more information, please contact:

  ValiRx plc                                           Tel: +44 (0) 2476 796496

  Dr Suzanne Dilly, CEO                                www.valirx.com (http://www.valirx.com/)

                                                       Suzanne.Dilly@valirx.com
 Cairn Financial Advisers LLP (Nominated Adviser)      Tel: +44 (0) 20 7213 088

  Liam Murray/Jo Turner/Ludovico Lazzaretti
 Cenkos Securities Limited (Joint Broker)              Tel: +44 (0) 20 7397 8900

  Dale Bellis/Michael Johnson (Sales)

 Giles Balleny/Callum Davidson (Corporate Finance)
 Turner Pope Investments (TPI) Limited (Joint Broker)  Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUSSRRUBUBRUR